[ad_1]
German scientists claim to have deciphered the cause of the rare blood clots associated with the Oxford/AstraZeneca and Johnson & Johnson coronavirus vaccines, and believe that the jab can be adjusted to prevent the reaction completely.
Rolf Marschalek, a professor at the Goethe University in Frankfurt, has been studying this rare disease since March. He said that his research shows that the problem lies in the adenovirus vector. Both vaccines use this adenovirus to deliver the Sars-Cov-2 sting. Spike protein virus enters the body.
Marschalek and other scientists said in an article that this delivery mechanism means that the vaccine delivers the spike protein to the nucleus, rather than the cytoplasmic fluid found inside cells where viruses normally produce proteins. Preprinted paper released on Wednesday.
Once in the nucleus, certain parts of the spike protein will splice or divide to form mutants, which cannot bind to the cell membrane where important immunity occurs. According to Marschalek’s theory, floating mutant proteins are secreted by cells into the body, triggering blood clots in approximately 100,000 people.
In contrast, mRNA-based vaccines (such as the prongs developed by BioNTech/Pfizer and Moderna) deliver the genetic material of the spikes into the cell sap and never enter the nucleus.
“When these… Viral genes will cause some problems in the nucleus,” Masalik told the Financial Times.
Among the 33 million people in the UK, 309 recorded a rare blood clotting reaction, which disrupted the injection effects of AstraZeneca and Johnson & Johnson, resulting in 309 deaths. In Europe, at least 142 people have experienced blood clots in 16 million vaccinators.
In response, the use of AstraZeneca has been restricted or suspended in more than a dozen countries/regions. Due to fears, after a short delay, Johnson & Johnson began to promote its vaccines in Europe in April, with warnings on its labels.
But Marschalek believes that if vaccine developers can modify the sequence of the spike protein to prevent it from splitting, it will be a straightforward “way.”
He said Johnson & Johnson has contacted Marsharik’s laboratory for guidance and is looking for ways to adjust its vaccine to prevent splicing.
According to Marschalek, the spike protein in Johnson & Johnson is already less prone to “splicing” than the spike protein in AstraZeneca’s jab, which makes the response less common. In the United States, 8 of the 7.4 million recipients of the Johnson & Johnson shooting reported this rare reaction.
“[J&J] It is currently trying to optimize its vaccine. He said. “Using the data we have, we can tell the company how to mutate these sequences to encode spike proteins in a way that prevents accidental splicing reactions. “
Johnson & Johnson said: “In the process of working with medical experts and global health agencies, we support ongoing research and analysis of this rare event. We look forward to reviewing and sharing data when it becomes available.”
Some scientists warned that Marsharik’s theory is one of many theories, and further evidence is needed to confirm his claims.
“There is evidence that the causality in splicing is missing…. Professor of Transfusion Medicine at the University of Bonn Johannes Oldenburg (Johannes Oldenburg) said. “This is still a hypothesis and needs to be proved by experimental data. “
Marshalik said that he has introduced the results of the laboratory’s research to the German government’s Paul Erich Institute and the country’s vaccination and immunization consulting agencies.
He said: “They were surprised by our findings because no one was thinking about the joint problem.”
[ad_2]
Source link
